Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CDC25B | P30305 | 2/20 | 0.40 |
| ▸ | CASP6 | P55212 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31348929 | 0.88 | KMT2A (0.48) | KMT2AKDM4EGFERRXFP1MEN1 | |
| SCHEMBL3822164 | 0.88 | KMT2A (0.48) | KMT2AKDM4EGFERRXFP1MEN1 | |
| SCHEMBL31634590 | 0.85 | CASP7 (0.47) | KMT2AKDM4EGFERRXFP1MEN1 | |
| SCHEMBL7115336 | 0.85 | CASP7 (0.47) | KMT2AKDM4EGFERRXFP1MEN1 | |
| SCHEMBL1352295 | 0.85 | KDM4E (0.48) | KMT2AKDM4EGFERRXFP1MEN1 | |
| SCHEMBL26132916 | 0.84 | DPP4 (0.54) | KMT2AKDM4EGFERRXFP1MEN1 | |
| SCHEMBL11396178 | 0.84 | CD44 (0.43) | KMT2AKDM4EGFERRXFP1MEN1 | |
| SCHEMBL7597578 | 0.84 | TDP1 (0.41) | KMT2AKDM4EGFERRXFP1MEN1 | |
| SCHEMBL1201950 | 0.79 | CA12 (0.57) | KDM4ETDP1MAPTPOLBPKM | |
| SCHEMBL28965508 | 0.79 | ALDH1A1 (0.43) | KMT2AKDM4EGFERRXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-7371866-B2 | Preparation of aromatic and heteroaromatic carboxylic acids by catalytic ozonolysis | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2008-05-13 | — | — | US | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005063385-A1 | METHOD FOR OXIDIZING SATURATED HYDROCARBONS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2005-07-14 | — | — | WO | disclosed |
| US-20030216577-A1 | Preparation of aromatic and heteroaromatic carboxylic acids by catalytic ozonolysis | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2003-11-20 | — | — | US | disclosed |
| EP-1362840-A1 | Process for the preparation of aromatic and heteroaromatic carboxylic acids via catalytic ozonolysis | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | KMT2A 3406/4885KDM4E 1934/4885GFER 1185/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | KMT2A 4429/4885KDM4E 4472/4885GFER 2256/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | KMT2A 1805/4885KDM4E 3541/4885GFER 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.